Trials / Completed
CompletedNCT00718237
Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)
A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of V260 in Healthy Infants in Japan
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 762 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 6 Weeks – 12 Weeks
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate whether V260 is effective and well tolerated in Japanese healthy infants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) | Rotateq orally administered 3 times |
| BIOLOGICAL | Comparator: Comparator: Placebo (unspecified) | Placebo orally administered 3 times |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2008-07-18
- Last updated
- 2017-04-13
- Results posted
- 2010-07-23
Source: ClinicalTrials.gov record NCT00718237. Inclusion in this directory is not an endorsement.